ライフサイエンスコーパス: improgan

1 ntinociceptive responses following intra-PAG improgan.

2 ptive responses produced by intraventricular improgan.

3 ficant role in the pain-relieving actions of improgan.

4 fects of clonidine, but not that produced by improgan.

5 Improgan (100-150 microg) produced near maximal antinoci

6 Separate intra-RM injections of improgan (30 microg) and WIN (8 microg) produced near-ma

7 Improgan (30 microg, icv) induced reversible, maximal an

8 Intracerebroventricular (icv) improgan (40-80 mug) produced complete, reversible, dose

9 Intracerebral (ic) microinjections of improgan (5-30 mug) into the rostral ventromedial medull

10 Improgan (60, 100 and 140 microg, intraventricular [ivt]

11 Improgan, a cimetidine derivative which lacks activity a

12 Improgan, a congener of the H(2) antagonist cimetidine,

13 Improgan, a non-opioid analgesic, is known to act in the

14 Pharmacological studies suggest that improgan activates descending pain-relieving circuits, b

15 These studies show that improgan activates pain-relieving mechanisms in the PAG

16 s, show that, like opioids and cannabinoids, improgan acts in the PAG and RVM to activate descending

17 Improgan, an analog of the histamine receptor antagonist

18 These studies demonstrate that improgan analgesia does not require intact MOR-1, DOR-1,

19 of action of this compound remains unknown, improgan analgesia was characterized presently with the

20 Similarly, improgan analgesia was equivalent in all three genotypes

21 ocked the antinociception elicited by i.c.v. improgan and i.c.v. morphine.

22 he antinociception produced by both intra-RM improgan and intra-RM WIN, but had no effects when given

23 responses following i.c. microinjections of improgan and the cannabinoid agonist WIN 55,212 (WIN) in

24 ne the effect of CC12, a recently discovered improgan antagonist which lacks affinity at CB(1) recept

25 treatment (4 mg/kg, i.p.) completely blocked improgan antinociception (80 microg, i.c.v.), suggesting

26 ects of the alpha(2) antagonist yohimbine on improgan antinociception were presently studied in rats

27 with yohimbine (30 microg) had no effect on improgan antinociception.

28 Similar studies with improgan demonstrated rimonabant-sensitive sites within

29 Unlike these other analgesics, improgan does not act in the spinal cord or in CNS areas

30 Unlike cannabinoid agonists, however, improgan does not produce locomotor inhibition at antino

31 Furthermore, CP-55,940 and improgan elicited maximal antinociception over the same

32 ed changes in the antinociceptive effects of improgan following once daily intraventricular injection

33 However, improgan has not been studied in any models of chronic p

34 ficant but incomplete (29-42%) antagonism of improgan hypothermia.

35 To assess the efficacy of improgan in an animal model of neuropathic pain, the eff

36 Improgan is a compound developed from histamine antagoni

37 Improgan is a derivative of cimetidine that induces non-

38 Improgan is an analog of the H(2) antagonist cimetidine

39 KOR-1 genes, and support the hypothesis that improgan-like analgesics act in the CNS by non-opioid me

40 ent findings suggest that brain-penetrating, improgan-like drugs developed for human use could be eff

41 Like several other classes of analgesics, improgan-like drugs seem to activate non-opioid, descend

42 rated suppression of RVM ON-cell activity by improgan may account for the presently-observed anti-all

43 investigated the pharmacological activity of improgan on core body temperature and nociceptive (tail

44 However, unlike the case with improgan, pretreatment with rimonabant completely blocke

45 Thus, improgan produced highly effective analgesia without the

46 Improgan produced large, dose- and time-related reductio

47 that, like cannabinoid agonists in the rat, improgan produces antinociception and hypothermia which

48 , suggesting the possible role of an unknown improgan receptor in both of these effects.

49 this brain area to be an important site for improgan's action.

50 eptors can induce antinociception, and since improgan showed affinity for these receptors in vitro, t

51 Furthermore, although improgan shows some affinity at alpha(2) receptors, this

52 inociception and the hypothermia produced by improgan, suggesting the possible role of an unknown imp

53 In DOR-1 mutant mice, improgan was equally effective in all three genotypes, d

54 acerebral and intrathecal microinjections of improgan were evaluated on thermal nociceptive responses